Superior SFA Results:
The Zilver PTX Randomized Trial is being conducted at 55 sites in the United States, Japan and Germany. This controlled trial focuses on moderate-length lesions to meet FDA requirements.
The Zilver PTX Single-Arm Trial is being conducted at 30 sites in Europe, Canada and Korea. This trial had much broader inclusion criteria than the randomized, controlled trial and thus includes a variety of “real-world” lesions.
Together, these complementary studies aim to provide a comprehensive assessment of Zilver PTX.
Trial Comparison
1 Dake M. The Zilver PTX randomized trial of paclitaxel-eluting stents for femoropopliteal disease: 24-month update. Presented at: 7th edition of the Leipzig Interventional Course (LINC) 2011; January 19-22, 2011; Leipzig, Germany.
2 Teßarek J. Update on 24 month single arm Zilver PTX study results and overview of 12 months randomized trial results. Presented at: 7th edition of the Leipzig Interventional Course (LINC) 2011; January 19-22, 2011; Leipzig, Germany.
3 Geenen GPJ. Zilver PTX stenting: effective treatment of PAD in the diabetic patient population. Presented at: 26th Annual Meeting of the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2010; October 2-6, 2010; Valencia, Spain.
4 Bosiers M, Deloose K. Zilver PTX study subgroup: long lesions and in-stent restenosis. Presented at: 26th Annual Meeting of the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2010; October 2-6, 2010; Valencia, Spain.
Results at a Glance
Trial Design
Instructions for Use:
Please refer to the Zilver PTX IFU for indications, contraindications, warnings, precautions and potential adverse events. PDF Download »
